StockMarketWire.com - Indivior said Tuesday US court had denied rival Dr. Reddy's Laboratories' motion to suspend the preliminary injunction previously granted by the District of New Jersey.

The preliminary injunction filed by Indivior against Dr. Reddy's Laboratories' prevents the sale of a generic version of the Indivior's opioid addiction treatment.

Dr. Reddy Laboratories appealed this ruling, and filed emergency motions, which has since been granted, seeking to expedite the appeal of the preliminary injunction -- the oral argument would be held the first week of October 2018.

'Today's ruling means that Dr. Reddy's Laboratories' continues to be prohibited from using, importing, selling, or offering to sell its generic buprenorphine/naloxone sublingual film productpending a favorable outcome for DRL on its appeal of the PI,' Indivior said.






At 8:43am: [LON:INDV] Indivior Plc share price was +2.05p at 312.95p



Story provided by StockMarketWire.com